



PRESS RELEASE  
27 March 2025 15:00:00 CET

## Stockholm3 study awarded best abstract in session at the 2025 European Association of Urology congress

**An independent international multicenter study on Stockholm3, led by Professor Derya Tilki, was awarded Best Abstract in session on Diagnostic and prognostic biomarkers in prostate cancer at the 2025 European Association of Urology (EAU) annual congress, held in Madrid, March 21–24.**

The awarded abstract presented real-world evidence of Stockholm3 performance outside Scandinavia, where most of the clinical data for Stockholm3 historically originates from, involving over 1,000 men across five centers in Germany, Switzerland, and Türkiye. The study compared Stockholm3 to PSA-based screening for detection of clinically significant prostate cancer (csPC), showing improved specificity and sensitivity across diverse European clinical practices.

### Key findings include:

- In men with PSA between 1.5–3 ng/ml, Stockholm3 identified csPC in 32% of those biopsied—cancers that would likely have been missed by PSA alone
- **27% reduction in unnecessary positive tests** when using Stockholm3  $\geq 11$  versus PSA  $\geq 3$  ng/ml
- **3% increase in detection of csPC** (ISUP grade  $\geq 2$  cancers)
- **Fewer low-grade (ISUP 1) cancers and benign biopsies**, enhancing diagnostic precision

“This study shows that Stockholm3 not only improves prostate cancer diagnostics within Scandinavian populations but also performs robustly across other European healthcare settings,” says Professor Derya Tilki, Principal Investigator of the study and MD at the Martini-Klinik Prostate Cancer Center at the University Hospital Hamburg-Eppendorf.

These findings reinforce the value of Stockholm3 in guiding MRI and biopsy decisions more effectively and optimizing care pathways for men at risk of prostate cancer.

The study adds to a growing body of international evidence supporting Stockholm3’s role in transforming early detection of aggressive prostate cancer, reducing overdiagnosis, and addressing global challenges in prostate cancer diagnostics.

A3P Biomedical AB (publ)



**For additional information, please contact:**

---

Cecilia Edström, acting CFO  
Telephone: +46 72 226 23 28  
Email: [cecilia.edstrom@a3p.com](mailto:cecilia.edstrom@a3p.com)

**About A3P Biomedical**

---

A3P Biomedical is a company that specializes in advanced prostate cancer diagnostics. A3P's main product, Stockholm3, is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit [www.a3p.com](http://www.a3p.com)

**About Stockholm3**

---

Stockholm3 is a blood-based prostate cancer test, that runs a combination of protein biomarkers, genetic biomarkers and clinical information through an algorithm to find the probability of clinically significant cancer at biopsy.

Stockholm3 has been evaluated in clinical studies including more than 90,000 men. It is extensively tested in large population-based screening trials, as well as in real world clinical utility studies in primary care, as a reflex test to PSA at values 1.5-20 ng/ml. Benefits include the ability to reduce unnecessary MRIs, benign and Grade Group 1 prostate biopsies for men with elevated PSA, while simultaneously improving detection of clinically significant cancers in men with low or normal PSA values. Using Stockholm3 leads to a more accurate risk assessment than the current PSA standard. Stockholm3 detects 41-89% more men with aggressive prostate cancer and, at the same time, reduces over-detection by 37-52% compared to PSA.

Multiple Stockholm3 studies have been published in high-impact journals such as The Lancet Oncology, Journal of Clinical Oncology, and European Urology. The studies address both the specificity and sensitivity of Stockholm3 in multi-ethnic populations as well as health-economic benefits of implementing it in clinical care. For more information about Stockholm3 and our clinical studies please visit [www.stockholm3.com/](http://www.stockholm3.com/)

**About prostate cancer**

---

Prostate cancer is the most common cancer in men. In 2020, the global incidence of new prostate cancer cases was 1.4 million, and prostate cancer specific mortality 370,000. Global prostate cancer incidence and mortality is expected to rise by 100% and 85% respectively by 2040, driven by an ageing population.

---

A3P Biomedical AB (publ)



## Attachments

---

[Stockholm3 study awarded best abstract in session at the 2025 European Association of Urology congress](#)